Jazz Pharmaceuticals plc (JAZZ)

Market Cap	8.17B
Revenue (ttm)	3.76B
Net Income (ttm)	-86.51M
Shares Out	63.13M
EPS (ttm)	-1.59
PE Ratio	n/a
Forward PE	6.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	473,313
Open	131.54
Previous Close	131.03
Day's Range	129.25 - 131.80
52-Week Range	120.64 - 160.96
Beta	0.71
Analysts	Strong Buy
Price Target	203.86 (+57.49%)
Earnings Date	Nov 8, 2023

About JAZZ

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) i...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 1, 2007
• Employees: 2,800
• Stock Exchange: NASDAQ
• Ticker Symbol: JAZZ

Financial Performance

In 2022, JAZZ's revenue was $3.66 billion, an increase of 18.26% compared to the previous year's $3.09 billion. Losses were -$224.06 million, -32.03% less than in 2021.

Analyst Forecast

According to 8 analysts, the average rating for JAZZ stock is "Strong Buy." The 12-month stock price forecast is $203.86, which is an increase of 57.49% from the latest price.

Price Target

$203.86

(57.49% upside)

Analyst Consensus: Strong Buy